Oncorus, Inc. (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors.
ONCR-177 is a Herpes Simplex Virus (HSV) product candidate. In the dose-escalation portion of the trial, ONCR-17 was well tolerated with no dose-limiting toxicities. With four evaluable patients in the monotherapy escalation portion of the trial, three of the eight evaluable patients indicated a clinical benefit after four weeks at the RP2D dose.
Additional surface lesion monotherapy expansion data are expected in mid-2022.
The company plans to begin enrollment in the dose combination expansion (Part 2) and the visceral lesion dose monotherapy escalation (Part 3) by the end of 2021.
The Cambridge, Mass. Oncorus claims to be "focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) Platform and Synthetic viral RNA (vRNA) Immunotherapy Platform."
ONCR shares are down $4.94, or 44.5% at $6.16, during the market session on the last check Friday.
